Ultra Rapid-Acting Inhaled Insulin Improves Glucose Control in Patients With Type 2 Diabetes Mellitus

ObjectiveTo determine whether the use of an inhaled insulin would improve HbA1c.MethodsThis study was performed in 20 type 2 diabetes mellitus (T2DM) participants with HbA1c values ≥7.5 (58) to ≤11.5% (102 mmol/mol) on a variety glucose-lowering regimens. Prandial Technosphere (TI) rapidly titrated based treatment algorithm using postprandial blood glucose calculate premeal doses. A 2-week baseline period followed by 12 weeks active TI. The primary outcome change HbA1c. Secondary outcomes included time range (time range: 70-180 mg/dL) obtained blinded continuous monitoring during and at end weeks. Goals were assess how safely initiate TI intensification, dosing requirements, establish effective dose uncontrolled T2DM.ResultsMean decreased −1.6% (−17 from 9.0% (75 7.4% (57 (P < .0001). Mean increased 42.2% 65.7% .0002). prandial doses 18 or 19 units for all meals. Time below 1.1% 2.6% post = .01).ConclusionTreatment dosed simple improved glycemic control measured both range, low rates hypoglycemia. These data add significantly understanding management T2DM patients whom is consideration.